...Monique Champagne president and CEO. She was VP of clinical research and regulatory affairs at Telesta Therapeutics Inc....

...Xa inhibitors Manufacturing Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Qapzola apaziquone Non-muscle invasive bladder cancer (NMIBC) Efficacy Telesta Therapeutics Inc....

...of Telesta for C$0.14 per share, payable in ProMetic stock (see BioCentury, Sept. 5 ). Telesta Therapeutics Inc....
...Belleville, Ontario ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Business: Cancer Nora Weintraub ProMetic Life Sciences Inc. Telesta Therapeutics Inc....

...reduce annualized operating expenses by $4.2M. 8/2/16 Telesta Therapeutics Inc. (TSX:TST; Pink:BNHLF) NA $30.7 NA 6/30/16 Profitable Telesta...
...complete response letter for a BLA for MCNA to treat high-risk non-muscle invasive bladder cancer. Telesta...
...wall-DNA complex (MCC). In late August, ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) agreed to acquire Telesta...

...ProMetic will acquire Telesta for C$0.14 per share, payable in ProMetic shares. The deal values Telesta...
...on 302.5 million shares outstanding on May 9. The price represents a 100% premium to Telesta’s...
...deal was announced. The deal is slated to close in early November. In early August, Telesta...

...expenditure controls” to focus on contractual obligations and licensing or acquiring clinical or near-clinical therapeutics. Telesta...
...March 31 and 32 at June 30. Ipsen Group (Euronext:IPN, Boulogne-Billancourt, France) will return to Telesta...
...risk non-muscle invasive bladder cancer outside of North America, South Africa, South Korea and Japan. Telesta...

...a phosphorodiamidate morpholino oligomer (PMO) that induces skipping of exon 51 in dystrophin mRNA. 3/8/16 Telesta Therapeutics Inc....
...from its Montreal, Quebec, manufacturing facility. In February, FDA issued a complete response letter to Telesta...
...III trial of the mycobacterial cell wall-DNA complex. For fiscal 1H15 ended Dec. 31, 2015, Telesta...

...came from Telesta’s Montreal manufacturing facility. In February, FDA issued a complete response letter to Telesta...
...FDA asked for an additional Phase III trial of the mycobacterial cell wall-DNA complex (MCC). Telesta...
...FDA to gain clarity on the letter (see BioCentury, Feb. 8). At Dec. 31, 2015, Telesta...

...FDA issued a complete response letter to Telesta for a BLA for MCNA to treat high-risk...
...bladder cancer (NMIBC) in patients who have failed first-line treatment with bacille Calmette-Guerin (BCG) therapy. Telesta...
...commercialize MCNA for NMIBC (see BioCentury, Nov. 23, 2015). Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Telesta Therapeutics Inc....

...Orphan Biovitrum AB (SSE:SOBI) Orfadin nitisinone oral suspension Hereditary tyrosinemia type I PDUFA date 2Q16 Telesta Therapeutics Inc....